Polyrizon (NASDAQ: PLRZ) Closes $17.0M Private Placement for Intranasal Hydrogel Development
Polyrizon (NASDAQ: PLRZ) successfully closes $17.0M private placement at $0.48 per unit. Funds to be used for corporate purposes. Aegis Capital Corp. acted as exclusive placement agent.
This news is significant as it highlights Polyrizon's financial success in securing funding for its innovative hydrogel technology. The company's development of intranasal hydrogels with barrier properties against viruses and allergens could have a positive impact on healthcare, potentially offering a preventative solution for nasal-related health issues.
